HMGB1 high affinity binding domain Box-A mutants

Details HMGB1 high affinity binding domain Box-A mutants HMGB1 high affinity binding domain Box-A mutants

2009-11-09

2011-11-15

Stoica, Elly-Gerald (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C435S069100, C530S350000

Reexamination Certificate

active

08058232

ABSTRACT:
The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases and which are therefore characterized by more favorable pharmacokinetic and pharmacodynamic profiles. Moreover, the present invention concerns the use of said polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and associated with RAGE.

REFERENCES:
patent: 7304034 (2007-12-01), Tracey et al.
patent: 694905 (2005-09-01), None
patent: 02/074337 (2002-09-01), None
patent: 02/092004 (2002-11-01), None
patent: 2004/022747 (2004-03-01), None
patent: 2004/046345 (2004-06-01), None
patent: 2005/025604 (2005-03-01), None
Isackson et al., “Production of HMG-3 by Limited Trypsin Digestion of Purified High-Mobility-Group Nonhistone Chromatin Proteins”, Biochimica Et Biophysica Acta, 748 (1983), 436-443.
Yang et al., “HMGB1 as a cytokine and therapeutic target”, Journal of Endotoxin Research, vol. 8, No. 6, 2002, pp. 469-472.
Kokkola et al, “Successful Treatment of Collagen-Induced Arthritis in Mice and Rats by Targeting Extracellular High Mobility Group Box Chromosomal Protein 1 Activity”, Arthritis & Rheumatism, vol. 48, No. 7, Jul. 2003, pp. 2052-2058.
Sparatore et al. “Extracellular processing of amphoterin generates a peptide active on erythroleukaemia cell differentiation”, Biochem J., (2001), 357, p. 569-574.
Andersson et al., “HMGB1 is a potent trigger of arthritis”, Journal of Internal Medicine, 2004, 255, p. 344-350.
Park et al., “Involvement of Toll-like Receptors 2 and 4 in Cellular Activation by High Mobility Group Box 1 Protein”, The Journal of Biological Chemistry, vol. 279, No. 9, Issue of Feb. 27, pp. 7370-7377, 2004.
Farid et al., “Differential Binding of HMG1, HMG2 and a Singe HMG Box to Cisplatin-Damaged DNA”, Toxicology and Applied Pharmacology, 141, p. 532-539, (1996).
Falciola et al., “Mutational analysis of the DNA binding domain A of chromosomal protein HMG1”, Nucleic Acids Research, 1994, vol. 22, No. 3, pp. 285-292.
Yang et al., “Reversing established sepsis with antagonists of endogenous high-mobility group box 1”, PNAS, Jan. 6, 2004, vol. 1, No. 1, pp. 296-301.

Affiliated with

Also associated with

Rating

HMGB1 high affinity binding domain Box-A mutants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HMGB1 high affinity binding domain Box-A mutants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HMGB1 high affinity binding domain Box-A mutants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4276318